Home Featured Page 268

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and...

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President...

Silo Wellness Partners with Kaivalya Kollectiv to Include 5-MeO-DMT In Psychedelic...

IntelGenx Announces Shareholder Approval of atai Investment

Exploring Oregon’s Measure 110 and The Future of Drug Policy Reform

IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of...

Henrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets...

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health...

PT243 – Dr. Fernando Espi Forcen and Dr. Franklin King of...

CB Therapeutics Closes on Oversubscribed Series A

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.